Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,469.72 +0.42 (+0.01%) Dow
39,159.64 +47.48 (+0.12%) Nasdaq
17,772.65 +54.99 (+0.31%) Bitcoin USD
61,076.99 -400.01 (-0.65%) CMC Crypto 200
1,265.04 -18.75 (-1.46%)
Bristol-Myers Squibb Co (BRM.SG)
| Previous close | 39.14 |
| Open | 39.29 |
| Bid | 39.69 x 500000 |
| Ask | 39.83 x 100000 |
| Day's range | 39.28 - 39.94 |
| 52-week range | 37.00 - 59.50 |
| Volume | |
| Avg. volume | 834 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksBristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $42.19, denoting a -0.09% change from the preceding trading day.
ZacksBristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
BenzingaFDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
Friday, the FDA granted accelerated approval to Bristol Myers Squibb & Co’s (NYSE:BMY) Krazati (adagrasib) in combination with cetuximab as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC), who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) res
